Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05673148 |
TitleTesting the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase
Phase 3
|
Date Added 2023-01-06 |
Location
Arizona, United States
California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy |
Tags
MSS/ MMRp
|
| NCT ID NCT05672316 |
TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy | Phase
Phase 1
|
Date Added 2023-01-05 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, Regorafenib |
Tags
MSS/ MMRp
|
| NCT ID NCT05653882 |
TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2022-12-16 |
Location
California, United States
Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2022-12-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
HX008, Investigator's Choice Chemotherapy |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05627635 |
TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-11-25 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT05611034 |
TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | Phase
Phase 1
|
Date Added 2022-11-09 |
Location
Canada
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | Phase
Phase 2
|
Date Added 2022-11-08 |
Location
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Belgium Brazil France Georgia Italy Russian Federation Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
Tags
MSS/ MMRp
|
| NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-11-08 |
Location
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05493683 |
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-08-09 |
Location
China,China,China,China,China,China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Disitamab vedotin, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | Phase
Phase 1
|
Date Added 2022-08-08 |
Location |
Prior IO Allowed No |
CRC-directed No |
Status
Not yet recruiting
|
Drugs
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
